Free Trial

Illumina (ILMN) Competitors

Illumina logo
$131.68 -3.32 (-2.46%)
(As of 11/20/2024 ET)

ILMN vs. PKI, AVTR, A, MTD, WAT, TECH, CRL, BIO, BRKR, and PACB

Should you be buying Illumina stock or one of its competitors? The main competitors of Illumina include Revvity (PKI), Avantor (AVTR), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Techne (TECH), Charles River Laboratories International (CRL), Bio-Rad Laboratories (BIO), Bruker (BRKR), and Pacific Biosciences of California (PACB).

Illumina vs.

Revvity (NYSE:PKI) and Illumina (NASDAQ:ILMN) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, Illumina had 17 more articles in the media than Revvity. MarketBeat recorded 17 mentions for Illumina and 0 mentions for Revvity. Illumina's average media sentiment score of 1.06 beat Revvity's score of 0.73 indicating that Illumina is being referred to more favorably in the news media.

Company Overall Sentiment
Revvity Positive
Illumina Positive

85.2% of Revvity shares are owned by institutional investors. Comparatively, 89.4% of Illumina shares are owned by institutional investors. 0.5% of Revvity shares are owned by insiders. Comparatively, 0.2% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Revvity has a net margin of 28.94% compared to Illumina's net margin of -36.10%. Revvity's return on equity of 11.17% beat Illumina's return on equity.

Company Net Margins Return on Equity Return on Assets
Revvity28.94% 11.17% 5.83%
Illumina -36.10%7.29%3.40%

Illumina received 607 more outperform votes than Revvity when rated by MarketBeat users. Likewise, 65.74% of users gave Illumina an outperform vote while only 58.69% of users gave Revvity an outperform vote.

CompanyUnderperformOutperform
RevvityOutperform Votes
500
58.69%
Underperform Votes
352
41.31%
IlluminaOutperform Votes
1107
65.74%
Underperform Votes
577
34.26%

Revvity has higher earnings, but lower revenue than Illumina. Illumina is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revvity$3.31B0.00$569.18M$7.68N/A
Illumina$4.50B4.64-$1.16B-$9.96-13.22

Illumina has a consensus target price of $164.00, suggesting a potential upside of 24.54%. Given Illumina's stronger consensus rating and higher probable upside, analysts plainly believe Illumina is more favorable than Revvity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revvity
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Illumina
1 Sell rating(s)
8 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.67

Revvity has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.

Summary

Illumina beats Revvity on 11 of the 18 factors compared between the two stocks.

Get Illumina News Delivered to You Automatically

Sign up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ILMN vs. The Competition

MetricIlluminaAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$20.88B$5.07B$5.03B$8.81B
Dividend YieldN/A0.46%5.16%4.06%
P/E Ratio-13.2223.87135.4117.82
Price / Sales4.644.391,160.9774.56
Price / Cash37.6940.7033.5332.53
Price / Book3.642.084.674.68
Net Income-$1.16B$515,312.50$119.07M$226.08M
7 Day Performance-7.42%-5.56%-1.83%-1.04%
1 Month Performance-9.32%-8.12%-3.60%1.04%
1 Year Performance37.21%-17.04%31.66%26.28%

Illumina Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ILMN
Illumina
4.5833 of 5 stars
$131.68
-2.5%
$164.00
+24.5%
+34.9%$21.41B$4.50B-13.229,300Positive News
PKI
Revvity
3.9421 of 5 stars
N/AN/AN/A$14.57B$3.31B15.0116,700Analyst Forecast
AVTR
Avantor
4.9762 of 5 stars
$20.14
+2.1%
$27.57
+36.9%
+3.6%$13.71B$6.97B43.7814,500Analyst Revision
A
Agilent Technologies
4.3995 of 5 stars
$128.57
+2.3%
$144.36
+12.3%
+12.8%$36.94B$6.83B26.6718,100Upcoming Earnings
News Coverage
Positive News
MTD
Mettler-Toledo International
4.1104 of 5 stars
$1,166.90
+0.5%
$1,338.75
+14.7%
+11.1%$24.49B$3.79B31.4617,300Positive News
WAT
Waters
4.1245 of 5 stars
$357.69
+3.8%
$365.85
+2.3%
+37.0%$20.47B$2.96B34.137,900
TECH
Bio-Techne
4.8558 of 5 stars
$68.72
+3.5%
$81.78
+19.0%
+8.1%$10.55B$1.16B73.113,100
CRL
Charles River Laboratories International
4.8024 of 5 stars
$187.90
+1.0%
$214.38
+14.1%
-1.4%$9.52B$4.13B23.5221,800Analyst Downgrade
BIO
Bio-Rad Laboratories
4.7149 of 5 stars
$323.69
+0.9%
$391.80
+21.0%
+6.3%$9.06B$2.58B-11.848,030Positive News
BRKR
Bruker
4.9986 of 5 stars
$53.37
+10.6%
$79.36
+48.7%
-12.9%$8.09B$2.96B25.669,707Dividend Announcement
Insider Trade
Gap Up
High Trading Volume
PACB
Pacific Biosciences of California
1.5162 of 5 stars
$1.72
flat
$3.63
+110.8%
-80.0%$471.05M$200.52M0.00730Analyst Revision

Related Companies and Tools


This page (NASDAQ:ILMN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners